How to Buy Adaptimmune Therapeutics Stock
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.
Adaptimmune Therapeutics stock last closed at $0.18, up 15% from the previous day, and has decreased 79.09% in one year. It has underperformed other stocks in the Biotechnology industry by 0.54 percentage points. Adaptimmune Therapeutics stock is currently +360% from its 52-week low of $0.04, and -79.09% from its 52-week high of $0.88.
As of Oct 15, 2025, there are 1.59B ADAP shares outstanding. The market capitalization of ADAP is $48.87M. In the last 24 hours, 74.29M ADAP shares were traded.
How to Buy Adaptimmune Therapeutics Stock
Not sure how to invest in Adaptimmune Therapeutics stock? Here's how.
- Decide where to buy Adaptimmune Therapeutics stock: You need to pick an online brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you determine where to buy Adaptimmune Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Fund your investment account: Choose your payment method and add your info.
- Research Adaptimmune Therapeutics stock: The Adaptimmune Therapeutics ticker symbol is ADAP. Is Adaptimmune Therapeutics stock a good investment? Should you buy shares of ADAP? How do ADAP's underlying business fundamentals look? Do top analysts think Adaptimmune Therapeutics is a good buy? Why has ADAP's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if ADAP is a good stock to buy).
- Make your ADAP trade: Decide if you will purchase ADAP shares at the current market price or use a limit order to buy ADAP shares at a specific price.
- Track your ADAP position: Create a watchlist to watch your new investment in Adaptimmune Therapeutics stock.
Step 1: Decide where to buy Adaptimmune Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy ADAP stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Tech to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in ADAP stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've finished signing up on the best stock market app for beginners, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of depositing funds into your new investment account.
Step 4: Research Adaptimmune Therapeutics stock
After you have decided on the best place to buy Adaptimmune Therapeutics stock, it's crucial to analyze their stock prior to investing, so you truly comprehend the risk and upside.
Adaptimmune Therapeutics Numbers
Adaptimmune Therapeutics Fundamentals
WallStreetZen was designed to help everyday investors perform better fundamental analysis.
You can see all of the due diligence checks on ADAP's stock page.
Is ADAP stock overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ADAP's true value.
You can access additional valuation research on ADAP's stock here.
How do ADAP Financials look?
Signs that ADAP is financially healthy:
- There are more short-term assets than short-term liabilities on the ADAP balance sheet.
Signs that ADAP is not financially healthy:
- There are more long-term liabilities than short-term assets on the ADAP balance sheet.
- ADAP has cash burn of 191667000. It does not have sufficient cash and short-term investments to cover this.
- ADAP profit margin has gone down from -51.3% to -260.8% in the past year.
- ADAP debt to equity ratio of -2.84 is negative.
- ADAP has $27.78M in cash and short term investments. This is not sufficient to cover its annual cash burn of $191.67M.
- Total ADAP debt is still negative.
Is ADAP stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 3 Equities analysts who track ADAP, the consensus analyst rating on ADAP is a Sell
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are forecasting on the Adaptimmune Therapeutics stock forecast page.
ADAP Technicals
ADAP Growth Numbers
Last year, ADAP revenue was $65.09M. In the last five year, ADAP's revenue has grown by 96.39% per year. This was faster than the Biotechnology industry average of 68%.
Find out more about ADAP's earnings and revenue performance here.
What are ADAP executives and large shareholders up to?
In the last year, executives and large shareholders at ADAP have sold more shares than they have bought.
Gavin Wood, Chief Financial Officer of ADAP, was the latest ADAP insider to sell. They sold $960.00 worth of ADAP shares on Sep 2, 2025.
Get more info about who owns ADAP stock here.
Does ADAP stock generate passive income?
No, Adaptimmune Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about ADAP?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your ADAP trade
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the best for newer investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount, use a limit order.
Press the Open Trade button and eToro will place your order.
If you want additional assistance investing in stocks on eToro, click the helpful video below:
Step 6: Track your ADAP position
Now that you own some ADAP shares, you'll want to keep up with your shares.
Create a watchlist to monitor your ADAP stock.
ADAP Feed
How to Buy Stock in Adaptimmune Therapeutics
To summarize, here are the 6 steps for buying Adaptimmune Therapeutics stock:
- Decide where to buy Adaptimmune Therapeutics stock
- Open your brokerage account
- Fund your investment account
- Research Adaptimmune Therapeutics stock
- Make your ADAP trade
- Track your ADAP position
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep track of your new investment in Adaptimmune Therapeutics, hit the button below to create your watchlist.
More "How To" Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.